Trials / Conditions / Recurrent Indolent Non-Hodgkin Lymphoma
Recurrent Indolent Non-Hodgkin Lymphoma
3 registered clinical trials studyying Recurrent Indolent Non-Hodgkin Lymphoma — 3 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Recruiting | Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Re NCT07166419 | Ohio State University Comprehensive Cancer Center | Phase 1 |
| Recruiting | Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma NCT06386315 | Mayo Clinic | Phase 2 |
| Recruiting | Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lym NCT05418088 | Sumithira Vasu | Phase 1 |